STABLE COMPOSITIONS OF ANTI-TIGIT ANTIBODIES, INDIVIDUALLY AND IN COMBINATION WITH ANTIBODIES AGAINST PROGRAMMED DEATH RECEPTOR 1 (PD-1), AND METHODS OF THEIR USE Russian patent published in 2024 - IPC A61K39/395 A61P31/12 A61P35/00 

FIELD: biotechnology.

SUBSTANCE: invention relates to a stable composition containing from about 10 mg/ml to about 200 mg/ml of an anti-TIGIT antibody or an antigen-binding fragment thereof, from about 5 mm to about 20 mm of L-histidine buffer, from about 6 % to about 8% (w/v) of sucrose, about 0.01% to about 0.10% (w/v) of polysorbate 80, about 1 mM to about 20 mM of L-methionine, and from about 10 mg/ml to about 200 mg/ml of an anti-PD1 antibody or antigen binding fragment thereof, where the formulation is a co-formulation and where pH of the stable formulation is from 5.3 to 6.2.

EFFECT: invention is effective for the treatment of malignant tumors and for the treatment of chronic infections.

19 cl, 8 dwg, 6 tbl, 8 ex